Navigation Links
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Date:6/4/2009

that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.<
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. First U.S. Patients Enrolled in the REALISM Continued Access Study
4. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
6. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
7. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
8. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
9. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015   ... to eliminate all preventable hospitalization, recently received confirmation ... its Remote Patient Intelligence (RPI) solution meets the ... FDA intends to exercise "Enforcement Discretion." ... not subject to further FDA regulatory requirements at ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, ... delivery platforms, has received Orphan Drug Designation from ... second drug product that uses NanoSmart,s proprietary drug ... of dactinomycin for the treatment of Ewing,s sarcoma, ... FDA granted NanoSmart,s Orphan Drug Designation on the ...
(Date:7/30/2015)... 30, 2015  Cleave Biosciences today announced that ... granted the company a key patent providing the ... CB-5083. This newly issued patent, "Fused ... U.S. 9,062,026, allows for claims on the composition ... oral inhibitor of p97, a critical enzyme that ...
Breaking Medicine Technology:FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 27 VirtualScopics, Inc. (Nasdaq: VSCP ), a ... announced that before the market opens on Thursday, November ... financial results. The company will host a conference call ... President and Chief Executive Officer, Jeff Markin, and Chief ...
... ARAY ), a global leader in the field of ... installed base has signed on to utilize Accuray,s Treatment Planning ... 10 percent of U.S. sites that had signed ... is designed to help customers maximize utilization of their CyberKnife ...
Cached Medicine Technology:VirtualScopics Schedules Third Quarter 2009 Earnings Announcement 2Accuray's Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers 2Accuray's Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers 3Accuray's Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... New Tool That Increases Training Capability , World renown body weight ... Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , The ...
(Date:7/30/2015)... ... July 30, 2015 , ... Using the latest online ... teach people more effective ways to prevent and manage major depression. , “Suicide is ... enough, so people fall through the cracks and die needlessly everyday,” says Walker. “I’m ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of Florida ... system, which has amassed largely enough throughout the years. Florida is the third state ... recent reduction of non violent drug offender’s prison sentences, Florida is beginning to take ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
(Date:7/30/2015)... Newark, NJ (PRWEB) , ... July 30, 2015 ... ... New Jersey's State-designated entity on behalf of the New Jersey Department of Health, ... for Health Information Technology, an agency of the U.S. Department of Health and ...
Breaking Medicine News(10 mins):Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... 6 Senetek PLC (OTC,Bulletin Board: SNKTY), a ... that target the science of healthy aging, today ... the 66th Annual Meeting,of the American Academy of ... presentation to the Academy, Dr. Sadick, a prominent ...
... damage follows soon after , , WEDNESDAY, Feb. 6 (HealthDay News) ... amyloid plaques, the harbingers of Alzheimer,s disease, can develop in ... said Dr. Bradley Hyman, leader of the group reporting the ... Once the plaques develop, damage is evident in nearby nerve ...
... PARK, N.J. and NEW YORK, Feb. 6 HLTH,Corporation ... WebMD Health Corp.,(Nasdaq: WBMD ), today announced that ... months ended December 31, 2007 at,approximately 4:00 pm (ET) ... conference call at 4:45 pm (ET) on that day ...
... PLC (OTC,Bulletin Board: SNKTY), a Life Sciences company ... science of healthy aging, today announced,the launch of ... Mr. Frank Massino, Senetek,s Chairman and Chief Executive ... to Senetek at this,significant time in our Company,s ...
... Oncology Metrics,a business that develops products and ... cancer, today announced the launch of the,first annual ... practices understand critical operating measures., This benchmark ... nationally. Practices of all size are invited to ...
... humans and are good models for human biology and ... created a zebrafish that is transparent throughout its life. ... its internal organs, and observe processes like tumor metastasis ... organism. , The fish, described in the February 7 ...
Cached Medicine News:Health News:Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2Health News:Alzheimer's Plaques Can Form in One Day 2Health News:HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 2Health News:Senetek PLC Announces Launch of New Website 2Health News:Oncology Metrics Launches the National Practice Benchmark: One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operational and Financial Performance 2Health News:Transparent fish to make human biology clearer 2Health News:Transparent fish to make human biology clearer 3
... HCFA Evaluation and Management guidelines in selecting billing ... information, it calculates the HCFA scores for each ... the effect of changing different parts of the ... you entered to create an audit trail of ...
... Coder is simply more than ... a handheld solution for accurate ... both individual physicians and small ... now comes in three versions ...
... is a computerized medical reference ... encompasses a wide array of ... sets and decision tree analysis ... medical educators, nurses and health ...
... mobileMICROMEDEX™ gives physicians, ... professionals reliable clinical information ... confirm treatment decisions. Clinicians ... in mobileMICROMEDEX because all ...
Medicine Products: